Original InvestigationSARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis
Graphical abstract
Index Words
Antibody levels
anti-spike serology
dialysis
coronavirus disease 2019 (COVID-19)
end-stage renal disease (ESRD)
immune response
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
third booster dose
BNT162b2
vaccine
vaccine adverse effects
Cited by (0)
Complete author and article information provided before references.
- ∗
A.-L.F. and P.H. contributed equally to this work.
© 2021 by the National Kidney Foundation, Inc.